Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach

BACKGROUND: Gastrointestinal stromal tumours (GISTs) with high-risk features have poor prognosis even if adjuvant treatment is given. Neoadjuvant imatinib may increase the cure rate by shrinking large GISTs and preserve organ function. METHODS: We conducted an Asian multinational phase II study for...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurokawa, Yukinori, Yang, Han-Kwang, Cho, Haruhiko, Ryu, Min-Hee, Masuzawa, Toru, Park, Sook Ryun, Matsumoto, Sohei, Lee, Hyuk-Joon, Honda, Hiroshi, Kwon, Oh Kyoung, Ishikawa, Takashi, Lee, Kyung Hee, Nabeshima, Kazuhito, Kong, Seong-Ho, Shimokawa, Toshio, Yook, Jeong-Hwan, Doki, Yuichiro, Im, Seock-Ah, Hirota, Seiichi, Hahn, Seokyung, Nishida, Toshirou, Kang, Yoon-Koo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520207/
https://www.ncbi.nlm.nih.gov/pubmed/28535156
http://dx.doi.org/10.1038/bjc.2017.144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520207/
https://www.ncbi.nlm.nih.gov/pubmed/28535156
http://dx.doi.org/10.1038/bjc.2017.144

Ejemplares similares